Government Policy & Regulation - US President Trump is urging 17 pharmaceutical manufacturers to voluntarily lower US prescription drug prices within 60 days to match global prices [1] - The call includes extending most favored nation (MFN) pricing to Medicaid [2] - Guaranteeing MFN pricing for newly launched drugs is also requested [2] - The request includes returning increased revenues from abroad to American patients and taxpayers [2] - Direct purchasing at MFN pricing is another point in the request [2] Industry Impact & Challenges - Implementing MFN pricing for newly launched drugs presents challenges, as US is often the initial launch market [3] - The industry will be watching the responses of companies like Lily, Pfizer, and AbbVie [4]

Well, pharma stocks are on the move as well. Our Angelica Peebles has that story. Angelica.>> Hey, John. Well, President Trump is sending letters to 17 pharmaceutical manufacturers calling on those manufacturers to take voluntary actions within the next 60 days to lower the price of prescription drugs in the US to similar prices around the world. So, he's calling for four things.He wants these companies to extend most favored nation pricing to Medicaid. He also wants them to guarantee MFN pricing for newly ...

today. Thanks. >> Good.Thank you. >> Okay. >> All right.Shares of Sanofi are lower this morning. The French pharmaceutical giant second quarter profits missed estimates but revenue topped expectations. The company is also raising its annual sales forecast on strong demand from its anti-inflammatory drug, Dupixent.That stock right now off by about 4%. Joining us right now to break it all down is Paul Hudson. He's Sanofi's CEO.And Paul, I have to say reading through the results, I was a little surprised to se ...

“We’re taking a pharmaceutical approach to nature,” says Joel Stanley, Ajna BioSciences’ 45-year-old CEO and founder. “Our entire process is totally organic, which means we could produce the first USDA-certified organic pharmaceutical.” https://t.co/9US1Ftcs8z ...

The biotech veteran was involved in the development of several approved drugs, likely making him a reassuring choice for a pharmaceutical industry that’s facing pressure from the Trump administration to lower prices and move drug manufacturing to the US https://t.co/ZnLX4JBobH ...

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. https://t.co/X1ri3kksyx https://t.co/X1ri3kksyx ...

Financial Performance - Telescope Innovations Corp. reported revenues of CAD 1.4 million for the fiscal quarter ended May 31, 2025, compared to CAD 1.2 million for the same quarter in FY 2024, reflecting a growth of approximately 14% [1][7] - The company incurred an adjusted EBITA loss of CAD 0.1 million, which is an increase from a loss of CAD 0.05 million in the comparable quarter of FY 2024 [1][7] - Total expenses for the quarter were CAD 1.9 million, up from CAD 1.4 million in the same quarter of FY 2024 [7] Operational Highlights - Telescope shipped its first battery-grade lithium sulfide (Li₂S) samples to major battery industry groups in Asia and North America, marking the initial customer evaluation of its proprietary low-temperature production process [4] - The company is part of the Arkansas Lithium Technology Accelerator, focusing on innovating the battery supply chain [4] - The DirectInject-LC™ product experienced significant growth, with sales and order pipelines more than doubling compared to Q3 2024 [7] Strategic Partnerships - Telescope is collaborating with Pfizer to develop a "Phase 1" Self-Driving Lab (SDL) platform, which aims to enhance chemistry research efficiency by up to 100 times compared to traditional methods [7] - The company is working with Mettler Toledo on a global distribution campaign, executing 11 application feasibility studies and participating in lead-generating events [7] Company Overview - Telescope Innovations Corp. focuses on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries, utilizing advanced technologies such as robotic platforms and artificial intelligence [6]

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. https://t.co/Q2rTHfUQwO https://t.co/Q2rTHfUQwO ...

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. (Photo: Charlotte’s Web) https://t.co/jywIrLpH9M https://t.co/WXLpzOxZXt ...

Group 1 - The article highlights significant announcements in the stock market from Sunday to Thursday, including "suspensions and resumption of trading, shareholding changes, investment wins, acquisitions, earnings reports, unlocks, and high transfers" [1] - Important announcements are marked in red to assist investors in identifying investment hotspots and preventing various black swan events, providing ample time for analysis and selection of suitable listed companies [1] - The article mentions a company that has achieved the supply of solid-state battery cathode materials in hundred-kilogram samples [1] Group 2 - Another company is noted for its services provided to certain military research institutes, integrating cloud computing, military industry, blockchain, robotics, AI, Huawei Harmony, and state-owned cloud [1] - A company in the innovative drug sector, particularly in weight loss drugs, is projected to have a net profit increase of over three times year-on-year in the first half of the year [1]